BioSpace News Archive

According to QY Research Medical, the nose reconstruction market size is expected to reach around $6.1 billion by 2030 and growing at a registered CAGR of 6.8% from 2021 to 2030.

According to QY Research Medical, the ophthalmic lasers market size was estimated at $1,207.81 million in 2020, and it is expected to surpass $1,909.71 million by 2030, registering a CAGR of 4.9% from 2021 to 2030.

According to QY Research Medical, the pharmacy automation system market size was reached at $5001 million in 2020, and is assessed to reach $11211 million by 2030, growing at a CAGR of 8.6% from 2021 to 2030.

A breakdown in how brain cells rid themselves of waste precedes the buildup of debris-filled plaques known to occur in Alzheimer’s disease, a new study in mice shows.

Bristol Myers Squibb (NYSE: BMY) today announced topline results from the Phase 3 Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-1) Immune Modulators clinical trial, sponsored by the National Institutes of Health (NIH).

The sports medicine market size was accounted at $8520 million in 2020, and is expected to reach around $12862 million by 2030, registering growth at a CAGR of 5.4% from 2021 to 2030.

According to QY Research Medical, the surgical sealants and adhesives market size was estimated at $2699.2 million in 2020, and is expected to hit $5,165.2 million by 2030, growing at a CAGR of 6.9% from 2021 to 2030.

A scientific team, led by the scientific founders of EtiraRx, has identified a small molecule, ERX-41, as a novel oral therapeutic agent that may have utility in treating multiple solid cancers, including triple negative breast cancer, glioblastoma, ovarian and pancreatic cancers.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, will host a global webcast to discuss new data from 1st line non-small cell lung cancer (NSCLC) patients participating in its Phase II TACTI-002 trial including an analyst Q&A.

Gain Therapeutics, Inc. announced that the company’s Chief Operating Officer, Matthias Alder, will present and host one-on-one meetings at the Jefferies Healthcare Conference taking place June 8-10 in New York, NY.